Clinical Study
The Strategy of Combining Antidepressants in the Treatment of Major Depression: Clinical Experience in Spanish Outpatients

Luis M. Martín-López,1 Jose E. Rojo,2 Karina Gibert,3 Juan Carlos Martín,3 Lyli Sperry,1 Lurdes Duño,1 Antonio Bulbena,1 and Julio Vallejo4

1 Institute of Neuropsychiatry and Addictions, Hospital del Mar, 08003 Barcelona, Spain
2 Department of Psychiatry, Hospital General Granollers Benito Menni CASM, 08400 Granollers, Barcelona, Spain
3 Statistics and Operation Research Department, Universitat Politècnica de Catalunya, 08034 Barcelona, Spain
4 Psychiatry Department, Hospital Universitari de Bellvitge, 08907 L’Hospitalet de Llobregat, Barcelona, Spain

Correspondence should be addressed to Luis M. Martín-López, 94779@parcdesalutmar.cat

Received 22 January 2011; Revised 3 April 2011; Accepted 14 April 2011

Academic Editor: Verinder Sharma

Copyright © 2011 Luis M. Martín-López et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. The combination of antidepressants is a useful tool in the treatment of major depression, especially in cases where there is a partial response to antidepressant monotherapy. However, the use of this strategy is a matter of controversy, and its frequency of use in clinical practice is not clear. The aim of our study is to assess the use of antidepressants combination in Spain by reviewing three databases used between 1997 and 2001.

Methods. Databases pertain to patients who are study subjects of major depression treatment. These databases are a result of studies performed in Spain and in which 550 psychiatrists participated. The total studied sample was comprised of \( N = 2,842 \) patients, aged over 18, fitting DSM-IV criteria for Major Depressive Episode. The percentage of patients who received more than one antidepressant and the types of combinations used was described. Subsequently, a comparative study between the group which received a combination of antidepressants (\( N = 64 \)) and the group which received antidepressant monotherapy (\( N = 775 \)) was performed.

Results. 27.1% of patients were on antidepressive monotherapy treatment, and 2.2% were on combination therapy. In the comparison of patients on combination therapy and monotherapy, there were significant differences only in episode duration (\( P = 0.001 \)). The most frequent combinations are SSRIs and tricyclic antidepressants. The active principle most widely combined is fluoxetine.

Conclusions. The prevalence of use of antidepressant combination therapy is 2.2% of the global sample and 8.3% of treated patients. Other than duration of the depressive episode, no clinical characteristics exclusive to patients who received combination rather than monotherapy were found. Our study found that the most frequent combination is SSRIs + TCAs, also being the most studied.

1. Introduction

According to numerous authors [1–5], the combination of antidepressants is a useful tool in the treatment of major depression. It is a therapeutic strategy indicated especially in cases where response to antidepressant monotherapy is partial [3]. These situations arise regardless of the type of therapy used. In a review of 102 studies of patients treated with tricyclic antidepressants (TCAs), results indicated that on average, 51% of subjects responded favorably [6]. Similarly, in a review of 39 studies of major depression treated with SSRIs 47% of patients had a sufficient response to treatment. Given that 15% of the general population is prone to suffer a major depression episode at some point in their life [7], a substantial number of patients may require a combination of antidepressants to achieve a full response. However, indications, selection, and use of these combinations are a matter of debate. Algorithms such as the Texas Medication Algorithm project (TMAP) [8], Canadian clinical guidelines [9, 10], Hirschfeld sequencing [11], the “Sequenced Treatment Alternatives to Relieve Depression” (STAR*D) [12, 13], and McIntyre’s algorithm [14] consider antidepressant combination therapy as second and third choice, to be applied only alternative monotherapies are
proven ineffective. However, other groups, such as the Spanish Study Group for Combination of Antidepressants (SGCAD) [15], place it as first choice. Evidence-based medicine including case series [16, 17], open trials [18–20], and randomized double-blind controlled studies [21–23] suggest the efficacy of combination therapy for resistant depression or for rapid treatment. However, as relatively little remains known about use of this approach, in the last few years, several authors have called for studies describing the actual prevalence of combination therapy use through patient, general population, or physician surveys [24–26] as well as prescription studies [27–30].

The objective of our study is to analyze the frequency of use of combination antidepressants (ADs) versus monotherapy among patients with major depression in Spain, and to assess whether there are clinical or other predictors of the use of combination AD through the review of three databases corresponding to naturalistic studies performed in 1997, 2000, and 2001.

2. Material and Methods

2.1. Databases. Databases from three naturalistic studies performed by Organon S.A., in which psychiatrists from public mental health institutions and general hospitals at three sites across Spain participated between November 1997 and July 2001, were analyzed (see Table 1). The databases complied with a series of criteria.

(i) Participants met DSM IV criteria for major depression

(ii) Information was available on any antidepressant drugs being taken by the patient prior to enrolment in the study.

(iii) Objectives, design and methodology without bias effect, such as nonexclusion of patients who are under treatment.

Databases were compiled as baseline information in the context of studies assessing the efficacy of the antidepressant mirtazapine (see Table 1). At baseline, information was collected on sociodemographic characteristics, AD use, basic clinical characteristics, and psychiatric history of all eligible patients undergoing treatment for or diagnosed with major depression during the study timeframe, regardless of medication use. All patients provided informed consent, and ethical approval was obtained from each institution.

2.2. Study Subjects. The studied sample comprised $N = 2,842$ patients. All subjects included in this analysis were over the age of 18, fit DSM-IV criteria for major depression episode, and had a minimum score of 9 in the Hamilton Depression Rating Scale (HAMD17). Exclusion criteria included pregnant or breastfeeding women, concomitant presence of another psychiatric disorder such a bipolar disorder as the primary diagnosis, any clinically relevant and/or nonstabilized renal, hepatic, cardiovascular, respiratory, endocrine, or cerebrovascular pathology, as well as other serious, progressive, incapacitating or high-risk physical pathologies, and any other anomaly in the patient’s health which could possibly interfere with the development of the study.

2.3. Study Variables. Sociodemographic and clinical variables were evaluated, including age, sex, marital status, previous history of depression, number of suicide attempts, characteristics of the current episode, duration of the episode, stressful life events, and the score on Hamilton's Depression Rating Scale (HAMD17). All drugs which were being taken by each patient at the start of the study were taken into account, including antidepressants, since the study did not exclude treated patients.

2.4. Data Analysis. A database was created by pooling databases from studies conducted in catchment areas in Spain, including 550 psychiatrists with a sample consisting of 2,842 patients (see Table 2). The percentage of patients who, at baseline, received more than one antidepressant and the types of combinations used was described.

Subsequently, a comparative study between the group which received a combination of antidepressants ($N = 64$) and the group which received antidepressant monotherapy ($N = 775$) was performed. The Kruskall Wallis and Mann Whitney tests were applied to continuous quantitative variables (age, age of onset, Hamilton Scale score), and the
The active principles most commonly combined were fluoxetine \( (n = 28 \text{ cases}) \), amitriptyline (22), paroxetine (17), and clomipramine (14).

Regarding the combination of SSRI + TCA, the most widely used combination was fluoxetine with amitriptyline, and the least used citalopram with clomipramine.

4. Discussion

Antidepressants combination treatments have become a popular method of treating refractory depression, enhancing therapeutic response in partial responders, and increasing the likelihood of more rapid response. Works from Nelson [6], Fava [31], Kelsey [32] and Shelton [33] support these strategies. Also, some researchers, Nelson [1], Besson [34], and Blier [23] have conducted studies using antidepressant combination from the beginning of the treatment in an attempt to obtain a more rapid onset of therapeutic action. The results from Besson et al. [23] provide evidence that combination therapy from the beginning of treatment provides superior clinical effectiveness in the treatment of major depression.

The objectives of this study were to assess the real prevalence of the use of antidepressant combinations in the treatment of major depression in our country and analyze the clinical characteristics of these patients.

Information on the use of combination antidepressant [35, 36] therapy is limited, and it remains uncertain whether the practice is widespread, and whether there are clinical indicators associated with its use. In this Spanish study, we found that among patients with major depression, the prevalence of combination therapy use was 8.3% in the patients who were receiving antidepressant treatment. The latter is comparable to rates varying from 1 to 5% reported in previous surveys conducted among subjects with major depression [25]. Rates of use were higher among patients with more persistent (>6 months) episodes of depression. Regardless of whether episodes were of longer or shorter (≤6 months) duration, use of combination therapy was not related to other clinical characteristics, including previous depressive episodes, patient sex, and level of depression. This suggests that efficacy of monotherapy, rather than other indicators of clinical complexity, may be the primary determinant of selection of combination therapy.

In the bibliographic revision, no studies of this kind are found. There are, however, other indirect methods to study the use of antidepressant combinations such as surveys and prescription studies, but the results obtained are all very different.

In the surveys, the results obtained are varied, ranging from those that do not detect this tendency [35, 36] to those that do, with different results: 1% [24], 2% [37], 5% [25], and 15% [26].

The second method is based on studying prescriptions received by patients in medical consultations. Though it is closer to the primary care reality, sometimes the combination's indication is unknown (since the studies aim to detect polypharmacy), and results are also very varied: 2–5% [27, 28], 5% [38], 10% [39], and 24-25% [29, 30].
Table 3: Characteristics of each database and the global sample.

|                     | MAR      | DIANA    | MEDAS    | GLOBAL   |
|---------------------|----------|----------|----------|----------|
| Year of study       | November | September | February | February |
|                     | 1997     | 1998     | 2001     | 2001     |
|                     | February | January   | July     | July     |
| Number of psychiatrists | 300      | 150      | 100      | 550      |
| Sample size         | 1261     | 877      | 704      | 2842     |
| Mean (sd) Age, years | 47.1 ± 14.2 | 47.5 ± 14.4 | 48.0 ± 15.0 | 47.4 ± 14.5 |
| Sex                 |          |          |          |          |
| Women               | 68.2%    | 69.2%    | 66.0%    | 68.0%    |
| Men                 | 31.8%    | 30.8%    | 34.0%    | 32.0%    |
| Marital status      |          |          |          |          |
| Unmarried           | —        | 16.4%    | 19.2%    | 17.6%    |
| Married             | —        | 62.7%    | 61.2%    | 62.1%    |
| Separated           | —        | 11.2%    | 10.7%    | 11.0%    |
| Widowed             | —        | 9.0%     | 8.3%     | 8.8%     |
| Unknown             | —        | 0.6%     | 0.4%     | 0.5%     |
| Age of onset        | 37.3 ± 14.5 | 36.4 ± 15 | 38.4 ± 13.8 | 37.3 ± 14.5 |
| Previous suicide attempts (any) | 7.8% | 8.9% | 8.9% | 8.5% |
| Mean number of suicides/patient | 0.14 | 0.15 | 0.14 | 0.14 |
| Any previous depressive episode |          |          |          |          |
| No                  | 51.1     | 49.8     | 51.5     | 50.8     |
| Yes                 | 48.9     | 50.2     | 48.5     | 49.2     |
| Other previous psychiatric pathologies | 15% | 27.9% | 26.9% | 21.7% |
| Unleashing factors  | 45.6%    | 50.4%    | 57.2%    | 50.0%    |
| Episode duration (%)|          |          |          |          |
| 2 weeks             | 5.2      | 3.4      | —        | 3.4      |
| 2 weeks-1 month     | 22.2     | 22.2     | 22.2     | 22.2     |
| 1–6 months          | 46.6     | 49.4     | 47.4     | 47.6     |
| 7–12 months         | 12.0     | 11.5     | 15.3     | 12.7     |
| Over 1 year         | 14.0     | 13.6     | 15.2     | 14.2     |
| Level of Depression |          |          |          |          |
| Mild (7–17)         | 20.7     | 22.3     | 14.0     | 19.5     |
| Moderate (18–24)    | 39.5     | 50.1     | 46.5     | 44.5     |
| Severe (25–52)      | 39.7     | 27.6     | 39.6     | 36.0     |
| Antidepressants taken|        |          |          |          |
| No ADs              | 69.9     | 72.1     | 70.3     | 70.7     |
| 1 AD                | 27.4     | 25.8     | 28.2     | 27.1     |
| ADs combination     | 2.7      | 2.1      | 1.5      | 2.2      |

The second objective was to assess whether there are some clinical characteristics that predict patient use of combination AD treatment.

In the analysis of the clinical characteristics of patients receiving combination of antidepressants, the only difference found is that these patients present a disorder of longer duration. It is not possible to say they are more complex patients because, although their age is greater, with a greater number of previous affective episodes, more suicide attempts and chronicity of the disorder, results were not statistically significant. Patients receiving antidepressant combinations are not different from the point of view of intensity of depressive symptoms according to the analysis of global results.
| Table 4: Comparative study of patients on one AD versus patients on AD combination. |
|---------------------------------|----------------|----------------|----------------|
|                                | One AD         | AD combination | Statistical Significance |
| Sample size                    | 775            | 64             | $P \leq .05$      |
| Age                            | $51.2 \pm 14.35$ | $53.1 \pm 12.06$ | $Z = -1.2$ \[P = .072\%\] |
| Sex                            |                |                | $\chi^2 = 0.91$ \[P = .34\] |
| Women                          | 72.7\%         | 69.6\%         |                |
| Men                            | 27.3\%         | 30.4\%         |                |
| Marital status                 |                |                | $\chi^2 = 3.58$ \[P = .058\] |
| Unmarried                      | 13.9\%         | 8.6\%          |                |
| Married                        | 62.8\%         | 77.1\%         |                |
| Separated                      | 11.5\%         | 5.7\%          |                |
| Widowed                        | 11.8\%         | 8.6\%          |                |
| Unknown                        |                | 0.6\%          |                |
| Age of onset                   | $39.8 \pm 15.1$ | $40.3 \pm 14.8$ | $Z = -0.59$ \[P = .86\] |
| Suicide attempts               | 10.7\%         | 16.5\%         | $\chi^2 = 1.56$ \[P = .21\] |
| Number of suicides/patient     | 0.19           | 0.36           |                |
| Previous depressive episodes   |                | $\chi^2 = 0.85$ \[P = .35\] |
| No                             | 36.4           | 42.0           |                |
| Yes                            | 63.6           | 58.0           |                |
| Other previous psychiatric disorders | 25.0\%       | 20.3\%         |                |
| Unleashing factors             | 46.7\%         | 56.5\%         |                |
| Duration of episode (%)        |                |                | $\chi^2 = 16.0$ \[P = .001\] |
| 2 weeks                        | 1.8            | 0.0            |                |
| 2 weeks-1 month                | 14.7           | 5.9            |                |
| 1–6 months                     | 47.2           | 38.2           |                |
| 7–12 months                    | 15.5           | 11.8           |                |
| over 1 year                    | 20.7           | 44.1           |                |
| Hamilton Scale                 | 21.69          | 21.69          | $Z = 0.287$ \[P = .77\] |
| Level of Depression (%)        |                |                | $\chi^2 = 3.6$ \[P = .165\] |
| Mild                           | 18.5           | 18.7           |                |
| Moderate                       | 40.6           | 50.0           |                |
| Severe                         | 41.0           | 31.2           |                |

| Table 5: Comparative study of Hamilton basal score one AD versus combination. |
|---------------------------------|----------------|----------------|----------------|
|                                | One AD         | Dt             | Combination    | $dt$ \[P \leq .05\] |
| Hamilton D-17 items            |                |                |                |                |
| (1) Depressed mood             | 2.58           | .77            | 2.76           | .93 \[+\] |
| (2) Feelings of guilt          | 1.29           | .88            | 1.24           | .91 \[\_\] |
| (3) Suicidal ideation          | 1.14           | .96            | 1.11           | 1.03 \[\_\] |
| (4) Early insomnia             | 1.49           | .65            | 1.48           | .72 \[\_\] |
| (5) Middle insomnia            | 1.09           | .63            | 1.05           | .58 \[\_\] |
| (6) Late insomnia              | 1.09           | .75            | 1.08           | .67 \[\_\] |
| (7) Work and activities        | 2.37           | .85            | 2.47           | .94 \[\_\] |
| (8) Retardation                | 1.06           | .85            | 1.14           | .85 \[\_\] |
| (9) Agitation                  | 1.14           | .86            | 1.17           | .77 \[\_\] |
| (10) Psychic anxiety           | 2.08           | .89            | 2.16           | .82 \[\_\] |
| (11) Somatic anxiety           | 1.86           | .78            | 1.89           | .76 \[\_\] |
| (12) Somatic symptoms (gastrointestinal) | 1.05       | .64            | .89            | .65 \[\_\] |
| (13) Somatic symptoms general  | 1.25           | .55            | 1.17           | .02 \[+\] |
| (14) Reduced libido            | 0.91           | .76            | 1.03           | .78 \[\_\] |
| (15) Hypochondriasis           | 1.30           | .97            | 1.25           | 1.02 \[\_\] |
| (16) Insight into illness      | .31            | .50            | .19            | .39 \[\_\] |
| (17) Loss of weight            | .70            | .70            | .41            | .00 \[+\] |
| Total                          | 22.67          | 5.91           | 22.34          | 5.52 \[\_\] |
from Hamilton’s scale. Results also showed an unexpected consideration, which was obtaining a nonsignificant result in items 10 and 11, which refer to anxiety symptoms, since depression that progresses with anxiety requires higher dosage of antidepressants and is often more dependent on combination therapy [40].

The literature reviewed shows no studies that analyze the clinical and sociodemographic characteristics of the patient receiving combined treatment. The revised works tend to analyze prescription tendencies or perform open trials where the efficacy of the combination strategy with different types of molecules is demonstrated.

However, some data obtained indirectly from the bibliographic revision can be contrasted with our study.

As such, in clinical characteristics, patients who are combining antidepressants are defined as more complex due to their tendency towards chronicity [37] or to personality disorder comorbidity [41]. These factors are indicators of combination [42].

Regarding the type of affective disorder, some studies aim to prove the efficacy of this strategy but highlight certain characteristics of these patients.

(i) Sethna [43], characterizes the patient who undergoes this strategy as a patient with a history of affective disorder of many years, with a tendency towards chronicity, dominant anxiety symptoms, without weight loss, early morning waking, or daily variation.

(ii) Seth et al. [16] consider the factors of chronicity and resistance of the affective disorder as indicators for the use of this strategy.

(iii) Mancini et al. [44] recommend the combination of SSRIs and noradrenergic antidepressants in depressed patients with obsessive symptoms.

(iv) Bauer et al. [30] described that patients with more severe depression had a greater likelihood of receiving a combination of antidepressant.

The analysis of the antidepressants used shows that the combinations and drugs found in our study present similar behaviours except for slight differences, when compared with the revised literature. The high frequency of the combination of SSRIs and TCAs corresponds to a greater amount of scientific articles dealing with this subject. The reasons are the obvious greater use of these molecules and the prevalence of depression’s monoaminergic theories in clinical practice, leading to the search for a full response when the use of SSRIs is accompanied by a partial response.

A more frequent use of fluoxetine is also detected, due to the fact that it is the first SSRI and most commonly used [45].

A difference is found in the type of TCA used. In our sample a greater use of amitriptiline is detected, while the literature shows that the most commonly used antidepressants are desipramine (not commercialized in our country), clomipramine, and nortriptyline. CAD is recommended to improve response and side effects (adjunctive therapy). Amitriptiline election would correspond better with the second indication.

### Table 6: Combinations types.

| Combinations types | Number |
|--------------------|--------|
| TCA + SSRI        | 35     |
| TCA + DUAL ADs    | 4      |
| SSRI + Mianserine | 4      |
| SSRI + SSRI       | 3      |
| SSRI + DUAL ADs   | 3      |
| TCA + TCA         | 3      |
| SSRI + Trazodone  | 2      |
| DUAL ADs + Mianserine | 2 |
| SSRI + Nefazodone | 1      |
| SSRI + TCAs + Nefazodone | 1 |
| Dual ADs + INA + Trazodone | 1 |
| SSRI + TCAs + INA | 1      |
| SSRI + TCAs(2)    | 1      |
| SSRI(2) + Dual ADs | 1   |
| SSRI(3) + Dual ADs | 1      |
| RIMA + Trazodone  | 1      |
| Total combinations | 64     |

Dual AD: venlafaxine. INA: Reboxetina.

Certain combinations are rarely advisable, such as the combination of two SSRIs, with little presence in the literature [46, 47] or totally inadvisable, such as the combinations of three and four antidepressants. In these cases, rather than speaking of combined therapies, the term to use would be polypharmacy.

Finally, the study of older database might be interpreted as not representing the current use of antidepressants. It is true that there are new molecules such as new selective serotonin reuptake inhibitors (SSRIs), escitalopram, and dual antidepressants as duloxetine. However, the current prescription pattern is similar. In our study, we want to highlight the frequency and how to use combinations of antidepressants.

The arguments for this is as follows.

(i) The recent history of depression treatment is repetitive and highlights three periods. First, tricyclic and tetracyclic antidepressants (TCAs) were the first-line treatment choice treatment; in the second, selective serotonin reuptake inhibitors (SSRIs). Now, we also use “third generation” antidepressants (venlafaxine, duloxetine).

(ii) In each of these periods (1965 and 1990), the combination of antidepressants becomes significant, especially in the decade of 90th with the widespread use of SSRIs [2, 48] when the strategy of combining ADs became more widely known.

### 5. Conclusions

The use of the antidepressant combination strategy is an issue that has been treated in a fluctuating and controversial
manner over the years. There are those who clearly support its use and those who question it [30].

The controversy heightens when the matter of this strategy’s real use in clinical practice is posed. Further efforts to evaluate this strategy are called for [49].

In this study, a method different from those revised in the literature is applied, showing a prevalence of use of 2.2% in the global sample and 8.3% in treated patients.

In the analysis of the study’s patients’ characteristics, no traits are found to be exclusive of the patient who receives antidepressant combinations. Therefore, there are no criteria in the selection of this strategy.

In regards to the type of combinations obtained in our study, SSRIs + antidepressants represent the most frequent option and the most studied and cited in the literature revised from the 90s. The years in which these studies were performed would also condition the choice of different molecules. This poses another question, since combinations acquire greater relevance with the appearance of SSRI which is better, to combine or use dual drugs?

In our opinion, the strategy of combination of antidepressants is influenced by trends or tendencies in prescription patterns. Despite the controversies and limitations of different studies, the combination of antidepressants is justified as a second or third option, especially in cases where response is partial.

The strengths of the study are that the data are representative of Spanish territory and offer results about the use antidepressant therapy in the practice.

Finally, we would like to comment on the limitations of our study, such as not learning about the psychiatrists who participated, which could elucidate the characteristics of the specialists who prescribe combinations, not knowing the dosage of the drugs and not being able to directly evaluate the efficacy of combination on a patient.

Acknowledgments

The authors would like to thank Dr. Jose Maria de Pedro of the Medical Department of Organon for providing the databases used in this study. They also thank to Dr. Michelle Mendez for the comments to a previous version of this manuscript.

References

[1] J. C. Nelson, C. M. Mazure, M. B. Bowers, and P. I. Jatlow, “A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression,” Archives of General Psychiatry, vol. 48, no. 4, pp. 303–307, 1991.

[2] J. C. Nelson, “Augmentation strategies with serotonergic-noradrenergic combinations,” Journal of Clinical Psychiatry, vol. 59, no. 5, pp. 65–69, 1998.

[3] J. E. Kelsey, “Treatment strategies in achieving remission in major depressive disorder,” Acta Psychiatrica Scandinavica, Supplement, vol. 106, no. 415, pp. 18–23, 2002.

[4] S. H. Kennedy, S. M. McCann, M. Masellis et al., “Combining bupropion SR with venlafaxine, paroxetin, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects,” Journal of Clinical Psychiatry, vol. 63, no. 3, pp. 181–186, 2002.

[5] N. Hannan, Z. Hamzah, H. O. Akpineloye, and D. Meagher, “Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness,” Journal of Psychopharmacology, vol. 21, no. 2, pp. 161–164, 2007.

[6] J. C. Nelson, “Overcoming treatment resistance in depression,” Journal of Clinical Psychiatry, vol. 59, no. 16, pp. 13–19, 1998.

[7] R. C. Kessler, “Sex and depression in the National Comorbidity Survey. II: cohort effects,” Journal of Affective Disorders, vol. 30, no. 1, pp. 15–26, 1994.

[8] M. L. Crisman, M. Trivedi, T. A. Pigott et al., “The Texas medication algorithm project: report of the Texas consensus conference panel on medication treatment of major depressive disorder,” Journal of Clinical Psychiatry, vol. 60, no. 3, pp. 142–156, 1999.

[9] Canadian Network for Mood and Anxiety Treatments, “Clinical Guidelines for the treatment of depressive disorders,” Canadian Journal of Psychiatry, vol. 46, supplement 1, pp. 58–90S, 2001.

[10] A. Duhoux, L. Fournier, C. T. Nguyen, P. Roberge, and R. Beveridge, “Guideline concordance of treatment for depressive disorders in Canada,” Social Psychiatry and Psychiatric Epidemiology, vol. 44, no. 5, pp. 385–392, 2009.

[11] R. M. A. Hirschedfeld, S. A. Montgomery, E. Aquiglia et al., “Partial response and nonresponse to antidepressant therapy: current approaches and treatment options,” Journal of Clinical Psychiatry, vol. 63, no. 9, pp. 826–837, 2002.

[12] “Sequenced Treatment and Alternatives to Relieve depression: A Study Funded by the National Institute of Mental Health,” About treatment options, December 2002, http://www.edc.gsp.th.pitt.edu/stard/public/about2.html.

[13] M. Fava, A. J. Rush, M. H. Trivedi et al., “Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study,” Psychiatric Clinics of North America, vol. 26, no. 2, pp. 457–494, 2003.

[14] R. S. McIntyre, A. Müller, D. A. Mancini, and E. S. Silver, “What to do if an initial antidepressant fails?” Canadian Family Physician, vol. 49, pp. 449–457, 2003.

[15] J. De la Gandara, L. Agüera, J. E. Rojo, and S. Ros, “Algorithm for the management of depression based on the antidepressant combinations proponed by the GEA Group,” Acta Psychiatry Scandinavica, vol. 112, no. 428, pp. 36–36, 2005.

[16] R. Seth, A. L. Jennings, J. Bindman, J. Phillips, and K. Bergmann, “Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression,” British Journal of Psychiatry, vol. 161, pp. 562–565, 1992.

[17] A. S. Gonul, F. Akdeniz, O. Donat, and S. Vaih, “Selective serotonin reuptake inhibitors combined with venlafaxine in depressed patients who had partial response to venlafaxine: four cases,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 27, no. 5, pp. 889–891, 2003.

[18] J. B. Weilburg, J. F. Rosenbaum, S. Meltzer-Brody, and J. Shushtari, “Tricylic augmentation of fluoxetine,” Annals of Clinical Psychiatry, vol. 3, no. 3, pp. 209–213, 1991.

[19] J. C. Nelson, C. M. Mazure, M. B. Bowers, and P. I. Jatlow, “A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression,” Archives of General Psychiatry, vol. 48, no. 4, pp. 303–307, 1991.

[20] F. López-Muñoz, C. Álamo, G. Rubio, P. Garcia-Garcia, and A. Pardo, “Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors,” Pharmacopsychiatry, vol. 40, no. 1, pp. 14–19, 2007.
[21] A. Medhus, S. Heskestad, and L. Tjemsland, “Mianserin added to tricyclic antidepressant in depressed patients nor responding to a tricyclic antidepressant alone. A randomized, placebo controlled, double blind study,” Nordic Journal of Psychiatry, vol. 48/5, pp. 355–358, 1994.

[22] J. C. Nelson, C. M. Mazeure, P. I. Jatlow, M. B. Bowers, and L. H. Price, “Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study,” Biological Psychiatry, vol. 55, no. 3, pp. 296–300, 2004.

[23] P. Blier, H. E. Ward, P. Tremblay, L. Laberge, C. Hébert, and R. Bergeron, “Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study,” American Journal of Psychiatry, vol. 167, no. 3, pp. 281–288, 2010.

[24] S. Byrne and A. J. Rothschild, “Psychiatrists’ responses to failure of maintenance therapy with antidepressants,” Psychiatric Services, vol. 48, no. 6, pp. 835–837, 1997.

[25] S. J. Fredman, M. Fava, A. S. Kienke, C. N. White, A. A. Nierenberg, and J. F. Rosenbaum, “Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current next-step practices,” Journal of Clinical Psychiatry, vol. 61, no. 6, pp. 403–408, 2000.

[26] J. De La Gándara, L. Agüera, F. Ferre, E. Rojo, and S. Ros, “Asociaciones de antidepresivos: resultados de una encuesta de opinión de psiquiatras españoles,” Psiquiatria Biológica, vol. 9, no. 5, pp. 184–190, 2002.

[27] K. J. Gregor, J. A. Riley, and D. K. Downing, “Concomitant use of anxiolytics and hypnotics with selective serotonin reuptake inhibitors,” Clinical Therapeutics, vol. 18, no. 3, pp. 521–527, 1996.

[28] K. J. Gregor, K. Way, C. H. Young, and S. P. James, “Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: How often does it really happen?” Journal of Affective Disorders, vol. 46, no. 1, pp. 59–67, 1997.

[29] J. A. Kotzan, R. Maclean, W. Wade et al., “Prevalence and patterns of concomitant use of selective serotonin reuptake inhibitors and other antidepressants in a high-cost pharmacy cohort,” Clinical Therapeutics, vol. 24, no. 2, pp. 237–248, 2002.

[30] M. Bauer, B. U. Monz, A. L. Montejo et al., “Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study,” European Psychiatry, vol. 23, no. 1, pp. 66–73, 2008.

[31] M. Fava, “Augmentation and combination strategies in treatment-resistant depression,” Journal of Clinical Psychiatry, vol. 62, no. 18, pp. 4–11, 2001.

[32] J. E. Kelsey, “Treatment strategies in achieving remission in major depressive disorder,” Acta Psychiatrica Scandinavica, Supplement, vol. 106, no. 415, pp. 18–23, 2002.

[33] R. C. Shelton, “The use of antidepressants in novel combination therapies,” Journal of Clinical Psychiatry, vol. 64, no. 2, pp. 14–18, 2003.

[34] A. Besson, N. Haddjeri, P. Blier, and C. De Montigny, “Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain,” European Neuropsychopharmacology, vol. 10, no. 3, pp. 177–188, 2000.

[35] S. J. Fredman, M. Fava, A. S. Kienke, C. N. White, A. A. Nierenberg, and J. F. Rosenbaum, “Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current next-step practices,” Journal of Clinical Psychiatry, vol. 61, no. 6, pp. 403–408, 2000.

[36] R. W. Lam, D. D. C. Wan, N. L. Cohen, and S. H. Kennedy, “Combining antidepressants for treatment-resistant depression: a review,” Journal of Clinical Psychiatry, vol. 63, no. 8, pp. 685–693, 2002.

[37] S. S. Shergill and C. L. E. Katona, “Pharmacological choices after one antidepressant fails: a survey of UK psychiatrists,” Journal of Affective Disorders, vol. 43, no. 1, pp. 19–25, 1997.

[38] P. McManus, A. Mant, P. Mitchell, D. Birkett, and J. Dudley, “Co-prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it?” British Journal of Clinical Pharmacology, vol. 51, no. 1, pp. 93–98, 2001.

[39] L. F. Agüera-Ortiz, S. González Parra, R. Sánchez Piedra, and T. Palomo, “Prescription patterns of older and newer antidepressants for geriatric depressive out-patients: a survey of use of antidepressants in elderly patients,” Actas Españolas de Psiquiatría, vol. 28, no. 6, pp. 343–352, 2000.

[40] R. T. Joffe and A. J. Levitt, “Antidepressant failure: augmentation or substitution?” Journal of Psychiatry and Psychology, vol. 20, no. 1, pp. 7–9, 1995.

[41] M. B. Nichol, G. L. Stimmel, and S. C. Lange, “Factors predicting the use of multiple psychotropic medications,” Journal of Clinical Psychiatry, vol. 56, no. 2, pp. 60–66, 1995.

[42] J. E. Rojo, S. Ros, L. Agüera, J. De La Gándara, and J. M. De Pedro, “Combined antidepressants: clinical experience,” Acta Psiquiatria Scandinavica, Supplement, vol. 112, no. 428, pp. 25–31, 2005.

[43] E. R. Sethna, “A study of refractory cases of depressive illnesses and their response to combined antidepressant treatment,” British Journal of Psychiatry, vol. 124, no. 3, pp. 265–272, 1974.

[44] C. Mancini, M. Van Ameringen, and P. Farvolden, “Does SSRI augmentation with antidepressants that influence noradrenergic function resolve depression in obsessive-compulsive disorder?” Journal of Affective Disorders, vol. 68, no. 1, pp. 39–65, 2002.

[45] A. Ubeda, E. Cardo, N. Sellés, R. Broseta, J. L. Trillo, and F. Fernández-Llimos, “Antidepressant utilization in primary care in a Spanish region: impact of generic and reference-based pricing policy (2000–2004),” Social Psychiatry and Psychiatric Epidemiology, vol. 42, no. 3, pp. 181–188, 2007.

[46] G. Bondolfi, C. Chautems, B. Rochat, G. Bertschy, and P. Baumann, “Non-response to citalopram in depressive patients: pharmakokinetic and clinical consequences of a fluvoxamine augmentation,” Psychopharmacology, vol. 128, no. 4, pp. 421–425, 1996.

[47] G. Bondolfi, C. Lissner, M. Kosel, C. B. Eap, and P. Baumann, “Fluoxetine augmentation in citalopram non-responders: pharmakokinetic and clinical consequences,” International Journal of Neuropsychopharmacology, vol. 3, no. 1, pp. 55–60, 2000.

[48] J. D. Amsterdam and M. Hornig-Rohan, “Treatment algorithms in treatment-resistant depression,” Psychiatric Clinics of North America, vol. 19, no. 2, pp. 371–386, 1996.

[49] A. J. Rush, “Combining antidepressant medications: a good idea?” American Journal of Psychiatry, vol. 167, no. 3, pp. 241–243, 2010.